Chronic Kidney Disease Clinical Trial
— OxCKD1Official title:
OxCKD1 - a Randomised Controlled Trial of the OxSalt1 Care Bundle to Help Renal Patients Learn How to Lower the Salt Content of Their Diets.
Verified date | December 2014 |
Source | University of Oxford |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: Research Ethics Committee |
Study type | Interventional |
Patients with kidney disease benefit from reducing the amount of salt in the food that they
eat. The benefits include lower blood pressure and better kidney function. Therefore,
lowering the amount of salt that is eaten could reduce the number of people who will develop
kidney failure. The effect on blood pressure could also reduce the number of strokes and
heart attacks. Similar benefits are also seen for people without kidney disease.
Guidelines for patients with kidney disease recommend that they lower the amount of salt
that they eat, but most patients do not manage to do this. The reasons for this are not
unclear, but are likely to reflect the difficulty that patients have in reducing the amount
of salt in their food and the nature of the advice that they are given.
The investigators have developed a package of interventions to help patients to make
healthier choices that will lower their salt intake. The package helps patients to learn
about salt in food and how to avoid it. It provide practical advice on cutting down on salt
using information booklets, text messages, emails, telephone calls, and a website.
Participants will be recruited from hospital kidney clinics and general practice. The
investigators will randomly allocate participants to receive either the normal care that
they would get or to receive the new package of interventions to help them lower salt. The
package of interventions will involve patients receiving text messages, telephone calls,
emails and written information. They will complete a questionnaire and collect urine samples
which will can be used to measure the amount of salt that they are eating. No more than 6
visits will be required. The study is funded by the British Renal Society which is a charity
that funds research to help patients with kidney disease.
Status | Completed |
Enrollment | 201 |
Est. completion date | November 2014 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study. - Male or Female, aged 18 years or above. - Diagnosed with CKD and an eGFR = 20 ml/min/1.73m2 - Participant has clinically acceptable laboratory data available to confirm the diagnosis. - Able (in the opinion of the Investigators) and willing to comply with all study requirements. - Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study Exclusion Criteria: - Female participants who is pregnant, lactating or planning pregnancy during the course of the study. - Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. - Inability to understand English or special communication needs because the interventions will use English and is not funded to deal with special communication needs. - Known salt losing nephropathy |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Oxford University Hospitals NHS Trust | Oxford | Oxfordshire |
Lead Sponsor | Collaborator |
---|---|
University of Oxford | British Renal Society |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Salt intake | To evaluate whether a new care bundle helps patients to reduce their salt intake. | 1 month | No |
Secondary | blood pressure | To assess the effects of the new care bundle on blood pressure. | 1 month, 3 months, 11 months | No |
Secondary | urine protein | To assess the effects of the new care bundle on urine albumin and protein levels. | 1 month, 3 months, 11 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |